Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multiple-Centered Study of AST2818 in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations

Trial Profile

Multiple-Centered Study of AST2818 in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Firmonertinib (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Allist Pharmaceuticals
  • Most Recent Events

    • 31 Jan 2021 Results of sub-group analysis assessing CNS efficacy of different AST2818 doses, presented at the 2020 World Conference on Lung Cancer.
    • 30 Jan 2020 Results (n=130) from NCT02973763 (n=14) and NCT03127449(n=116), assessing clinically efficacy with an acceptable toxicity profile in advanced NSCLC patients (including those with CNS metastases) with EGFR T790M mutation, published in the Journal of Thoracic Oncology
    • 02 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top